Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 151 to 165 of 182 results for pembrolizumab

  1. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

    Technology appraisal guidance
    Discontinued

  3. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1060)

    Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    8 May 2025

    Sections for TA1060

  4. Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

    This guidance has been updated and replaced by NICE technology appraisal guidance 766.

    Withdrawn guidance

  5. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

    Technology appraisal guidance
    Published
    21 February 2024
    View recommendations

    Sections for TA952

  9. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

    This guidance has been updated and replaced by NICE technology appraisal guidance 531.

    Withdrawn guidance

  10. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Withdrawn guidance

  11. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

    This guidance has been updated and replaced by NICE technology appraisal guidance 692.  

    Withdrawn guidance

  12. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

    This guidance has been updated and replaced by NICE technology appraisal guidance 770.

    Withdrawn guidance

  13. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    17 August 2022
    View recommendations

    Sections for TA818

  14. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

    Technology appraisal guidance
    Published
    12 May 2025

    Sections for TA1062

  15. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development Reference number: GID-TA11582 Expected publication date: TBC

    Technology appraisal guidance
    In development